RBC Capital raised the firm’s price target on Edwards Lifesciences to $95 from $82 and keeps an Outperform rating on the shares. The company’s Q4 results topped estimates as TAVR sales beat expectations, and the management’s 2024 guide of 8%-10% “looks achievable” with room for upside, the analyst tells investors in a research note. RBC adds that its price target increase reflects the recent run-up in the stock price.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EW:
- Edwards Lifesciences Corp. (EW) Q4 Earnings Cheat Sheet
- Wells upgrades Edwards Lifesciences, says tricuspid opportunity underappreciated
- Edwards Lifesciences upgraded to Overweight from Equal Weight at Wells Fargo
- Edwards Lifesciences earns FDA approval for Evoque tricuspid valve
- Early notable gainers among liquid option names on January 31st
